The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells

Virology

Volumn 423, Issue 2, 2012, Pages 175-186

  Alexandre, Kabamba B ^a   Gray, Elin S ^a   Mufhandu, Hazel ^b   McMahon, James B ^c   Chakauya, Ereck ^b   O'Keefe, Barry R ^c   Chikwamba, Rachel ^b   Morris, Lynn ^a  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cyanovirin N; DC SIGN receptor; Griffithsin; HIV 1 gp120; Mannose rich glycans; Scytovirin

Indexed keywords

CD209 ANTIGEN; CD4 ANTIGEN; CYANOVIRIN N; GRIFFITHSIN; LECTIN; SCYTOVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SEXUAL TRANSMISSION; VIRUS INHIBITION; VIRUS TRANSMISSION;

ALGAL PROTEINS; BACTERIAL PROTEINS; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL LINE; DOWN-REGULATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LECTINS; LECTINS, C-TYPE; PLANT LECTINS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECEPTORS, HIV;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855816891     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.12.001     Document Type: Article

References (70)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329(5996):1168-1174.
2. Alexandre K.B., Gray E.S., Lambson B.E., Moore P.L., Choge I.A., Mlisana K., Karim S.S., McMahon J., O'Keefe B., Chikwamba R., Morris L. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, griffithsin, cyanovirin-N and scytovirin. Virology 2010, 402(1):187-196.
3. Alexandre K.B., Gray E.S., Pantophlet R., Moore P.L., McMahon J.B., Chakauya E., O'Keefe B.R., Chikwamba R., Morris L. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J. Virol. 2011, 85(17):9039-9050.
4. Balzarini J. Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet Infect. Dis. 2005, 5(11):726-731.
5. Balzarini J., Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007, 369:787-797.
6. Balzarini J., Van Herrewege Y., Vermeire K., Vanham G., Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 2007, 71(1):3-11.
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
8. Banerjee, K., Michael, E., Eggink, D., van Montfort, T., Lasnik, A.B., Palmer, K.E., Sanders, R.W., Moore, J.P., Klasse, P.J., in press. Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res. Hum. Retroviruses. doi:. doi:10.1089/aid.2011.0101.
9. Barrientos L.G., Louis J.M., Botos I., Mori T., Han Z., O'Keefe B.R., Boyd M.R., Wlodawer A., Gronenborn A.M. The domain-swapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures. Structure 2002, 10(5):673-686.
10. Bokesch H.R., O'Keefe B.R., McKee T.C., Pannell L.K., Patterson G.M., Gardella R.S., Sowder R.C., Turpin J., Watson K., Buckheit R.W., Boyd M.R. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 2003, 42(9):2578-2584.
11. Bolmstedt A.J., O'Keefe B.R., Shenoy S.R., McMahon J.B., Boyd M.R. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol. Pharmacol. 2001, 59(5):949-954.
12. Botos I., Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog. Biophys. Mol. Biol. 2005, 88(2):233-282.
13. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., Gulakowski R.J., Wu L., Rivera M.I., Laurencot C.M., Currens M.J., Cardellina J.H., Buckheit R.W., Nara P.L., Pannell L.K., Sowder R.C., Henderson L.E. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 1997, 41(7):1521-1530.
14. Burleigh L., Lozach P.Y., Schiffer C., Staropoli I., Pezo V., Porrot F., Canque B., Virelizier J.L., Arenzana-Seisdedos F., Amara A. Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. J. Virol. 2006, 80(6):2949-2957.
15. Cavrois M., Neidleman J., Greene W.C. The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathog. 2008, 4(6):e1000051.
16. Choge I., Cilliers T., Walker P., Taylor N., Phoswa M., Meyers T., Viljoen J., Violari A., Gray G., Moore P.L., Papathanosopoulos M., Morris L. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res. Hum. Retroviruses 2006, 22(5):458-465.
17. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
18. Cilliers T., Nhlapo J., Coetzer M., Orlovic D., Ketas T., Olson W.C., Moore J.P., Trkola A., Morris L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J. Virol. 2003, 77(7):4449-4456.
19. Cutler B., Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 2008, 8(11):685-697.
20. Esser M.T., Mori T., Mondor I., Sattentau Q.J., Dey B., Berger E.A., Boyd M.R., Lifson J.D. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 1999, 73(5):4360-4371.
21. Ferir G., Palmer K.E., Schols D. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 2011, 417(2):253-258.
22. Fischetti L., Barry S.M., Hope T.J., Shattock R.J. HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS 2009, 23(3):319-328.
23. Go E.P., Hewawasam G., Liao H.X., Chen H., Ping L.H., Anderson J.A., Hua D.C., Haynes B.F., Desaire H. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J. Virol. 2011, 85(16):8270-8284.
24. Gray E.S., Moore P.L., Choge I.A., Decker J.M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K., Shaw G.M., Karim S.S., Williamson C., Morris L. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 2007, 81(12):6187-6196.
25. Gurney K.B., Elliott J., Nassanian H., Song C., Soilleux E., McGowan I., Anton P.A., Lee B. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J. Virol. 2005, 79(9):5762-5773.
26. Hong P.W., Flummerfelt K.B., de Parseval A., Gurney K., Elder J.H., Lee B. Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. J. Virol. 2002, 76(24):12855-12865.
27. Hong P.W., Nguyen S., Young S., Su S.V., Lee B. Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J. Virol. 2007, 81(15):8325-8336.
28. Hussain L.A., Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995, 85(3):475-484.
29. Johnston M.I., Fauci A.S. An HIV vaccine-evolving concepts. N. Engl. J. Med. 2007, 356(20):2073-2081.
30. Kouokam J.C., Huskens D., Schols D., Johannemann A., Riedell S.K., Walter W., Walker J.M., Matoba N., O'Keefe B.R., Palmer K.E. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One 2011, 6(8):e22635.
31. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
32. Lambert A.A., Gilbert C., Richard M., Beaulieu A.D., Tremblay M.J. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 2008, 112(4):1299-1307.
33. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106(3):263-266.
34. Lederman M.M., Offord R.E., Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 2006, 6(5):371-382.
35. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 1990, 265(18):10373-10382.
36. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(16):10108-10125.
37. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 2006, 80(23):11776-11790.
38. Li J., Jiang H., Wen W., Zheng J., Xu G. The dendritic cell mannose receptor mediates allergen internalization and maturation involving notch 1 signalling. Clin. Exp. Immunol. 2010, 162(2):251-261.
39. Liao C.F., Wang S.F., Lin Y.T., Ho D.D., Chen Y.M. Identification of the DC-SIGN-interactive domains on the envelope glycoprotein of HIV-1 CRF07_BC. AIDS Res. Hum. Retroviruses 2011, 27(8):831-839.
40. Liu Y., Liu H., Kim B.O., Gattone V.H., Li J., Nath A., Blum J., He J.J. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J. Virol. 2004, 78(8):4120-4133.
41. Liu X., Lagenaur L.A., Simpson D.A., Essenmacher K.P., Frazier-Parker C.L., Liu Y., Tsai D., Rao S.S., Hamer D.H., Parks T.P., Lee P.P., Xu Q. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 2006, 50(10):3250-3259.
42. Lue J., Hsu M., Yang D., Marx P., Chen Z., Cheng-Mayer C. Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J. Virol. 2002, 76(20):10299-10306.
43. McCoombe S.G., Short R.V. Potential HIV-1 target cells in the human penis. AIDS 2006, 20(11):1491-1495.
44. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33(4):542-554.
45. Mori T., O'Keefe B.R., Sowder R.C., Bringans S., Gardella R., Berg S., Cochran P., Turpin J.A., Buckheit R.W., McMahon J.B., Boyd M.R. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 2005, 280(10):9345-9353.
46. Moulaei T., Botos I., Ziolkowska N.E., Bokesch H.R., Krumpe L.R., McKee T.C., O'Keefe B.R., Dauter Z., Wlodawer A. Atomic-resolution crystal structure of the antiviral lectin scytovirin. Protein Sci. 2007, 16(12):2756-2760.
47. Norvell M.K., Benrubi G.I., Thompson R.J. Investigation of microtrauma after sexual intercourse. J. Reprod. Med. 1984, 29(4):269-271.
48. O'Keefe B.R., Vojdani F., Buffa V., Shattock R.J., Montefiori D.C., Bakke J., Mirsalis J., d'Andrea A.L., Hume S.D., Bratcher B., Saucedo C.J., McMahon J.B., Pogue G.P., Palmer K.E. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(15):6099-6104.
49. Patterson B.K., Landay A., Siegel J.N., Flener Z., Pessis D., Chaviano A., Bailey R.C. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am. J. Pathol. 2002, 161(3):867-873.
50. Piguet V., Sattentau Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 2004, 114(5):605-610.
51. Piquet V., Sattenteau Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 2004, 114(5):605-610.
52. Pohlmann S., Baribaud F., Doms R.W. DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol. 2001, 22(12):643-646.
53. Ramjee G., Doncel G.F., Mehendale S., Tolley E.E., Dickson K. Microbicides 2008 conference: from discovery to advocacy. AIDS Res. Ther. 2008, 5:19.
54. Shattock R.J., Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 2003, 1(1):25-34.
55. Soilleux E.J., Coleman N. Expression of DC-SIGN in human foreskin may facilitate sexual transmission of HIV. J. Clin. Pathol. 2004, 57(1):77-78.
56. Spear G.T., Zariffard M.R., Xin J., Saifuddin M. Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology 2003, 110(1):80-85.
57. Stein S.E.G. Transmission and epidemiology. Human immunodeficiency virus 2003, 5:1-5:22. International Medical Press. D.D. Richman (Ed.).
58. Tsai C.C., Emau P., Jiang Y., Tian B., Morton W.R., Gustafson K.R., Boyd M.R. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 2003, 19(7):535-541.
59. Tsai C.C., Emau P., Jiang Y., Agy M.B., Shattock R.J., Schmidt A., Morton W.R., Gustafson K.R., Boyd M.R. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 2004, 20(1):11-18.
60. van Harmelen J., Williamson C., Kim B., Morris L., Carr J., Karim S.S., McCutchan F. Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res. Hum. Retroviruses 2001, 17(16):1527-1531.
61. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
62. Wu L., Martin T.D., Carrington M., KewalRamani V.N. Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission. Virology 2004, 318(1):17-23.
63. Xiong C., O'Keefe B.R., Botos I., Wlodawer A., McMahon J.B. Overexpression and purification of scytovirin, a potent, novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Protein Expr. Purif. 2006, 46(2):233-239.
64. Xu W., Smith-Franklin B.A., Li P.L., Wood C., He J., Du Q., Bhat G.J., Kankasa C., Katinger H., Cavacini L.A., Posner M.R., Burton D.R., Chou T.C., Ruprecht R.M. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J. Hum. Virol. 2001, 4(2):55-61.
65. Yu H.J., Reuter M.A., McDonald D. HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog. 2008, 4(8):e1000134.
66. Zhang M., Gaschen B., Blay W., Foley B., Haigwood N., Kuiken C., Korber B. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14(12):1229-1246.
67. Zhou J.Y., Montefiori D.C. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 1997, 71(3):2512-2517.
68. Ziolkowska N.E., Wlodawer A. Structural studies of algal lectins with anti-HIV activity. Acta Biochim. Pol. 2006, 53(4):617-626.
69. Ziolkowska N.E., O'Keefe B.R., Mori T., Zhu C., Giomarelli B., Vojdani F., Palmer K.E., McMahon J.B., Wlodawer A. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 2006, 14(7):1127-1135.
70. Zwick M.B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 2001, 75(24):12198-12208.